Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I/II study and pharmacokinetic analysis

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1112-1119

  Tawbi, H A ^a,b,c   Beumer, J H ^a,b,c,d   Tarhini, A A ^a,b   Moschos, S ^a,b   Buch, S C ^e   Egorin, M J ^a,c   Lin, Y ^b,c,f   Christner, S ^a,c   Kirkwood, J M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Melanoma Program   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Pharmaceutical Sciences Department   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Decitabine; Melanoma; Pharmacokinetic analysis; Temozolomide

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; GROWTH FACTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; ATAXIA; BACKACHE; BLOOD TOXICITY; BONE MARROW DISEASE; BRAIN METASTASIS; CANCER CONTROL; CANCER RESISTANCE; CANCER STAGING; CANCER TISSUE; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DESQUAMATION; DIARRHEA; DISEASE DURATION; DIZZINESS; DNA METHYLATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; ILEUS; INFECTION; LETHARGY; LYMPHOCYTOPENIA; MALAISE; MALE; METABOLIC DISORDER; METASTATIC MELANOMA; MGMT GENE; MMR GENE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOSIS; THROMBUS; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 84875597205     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds591     Document Type: Article

References (42)

1. American Cancer Society. In. http://www.cancer.org/ 2012.
2. Jemal A, Saraiya M, Patel P et al.. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011; 65: S17-S25 e11-13.
3. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
4. Hodi FS, O'Day SJ, McDermott DF et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
5. Robert C, Thomas L, Bondarenko I et al.. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
6. Flaherty KT, Puzanov I, Kim KB et al.. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
7. Chapman PB, Hauschild A, Robert C et al.. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
8. Middleton MR, Grob JJ, Aaronson N et al.. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
9. Bedikian AY, Millward M, Pehamberger H et al.. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
10. Schadendorf D, Ugurel S, Schuler-Thurner B et al.. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
11. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12: 328-331.
12. Barvaux VA, Ranson M, Brown R et al.. Dual repair modulation reverses temozolomide resistance in vitro. Mol Cancer Ther 2004; 3: 123-127.
13. Issa JP, Garcia-Manero G, Giles FJ et al.. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2?-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640.
14. Gollob JA, Sciambi CJ, Peterson BL et al.. Phase I trial of sequential low-dose 5-aza-2?-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006; 12: 4619-4627.
15. Sobol RW, Tawbi H, Jukic D et al.. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma. J Clin Oncol 2006; 24: 8015.
16. Korn EL, Liu PY, Lee SJ et al.. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
17. Stewart DJ, Issa JP, Kurzrock R et al.. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009; 15: 3881-3888.
18. Schrump DS, Fischette MR, Nguyen DM et al.. Phase I study of decitabinemediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12: 5777-5785.
19. Koshy M, Dorn L, Bressler L et al.. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000; 96: 2379-2384.
20. Tawbi HA, Buch SC. Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 2010; 8: 259-266.
21. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296-307.
22. Watson AJ, Middleton MR, McGown G et al.. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer 2009; 100: 1250-1256.
23. Tawbi HA, Villaruz L, Tarhini A et al.. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer 2011; 105: 773-777.
24. Kefford RF, Thomas NP, Corrie PG et al.. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer 2009; 100: 1245-1249.
25. Gajewski TF, Sosman J, Gerson SL et al.. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005; 11: 7861-7865.
26. Spiro TP, Gerson SL, Liu L et al.. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59: 2402-2410.
27. Schilsky RL, Dolan ME, Bertucci D et al.. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000; 6: 3025-3031.
28. Quinn JA, Desjardins A, Weingart J et al.. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005; 23: 7178-7187.
29. Quinn JA, Jiang SX, Reardon DA et al.. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009; 27: 1262-1267.
30. Ryan CW, Dolan ME, Brockstein BB et al.. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 2006; 58: 634-639.
31. Ranson M, Hersey P, Thompson D et al.. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007; 25: 2540-2545.
32. Tolcher AW, Gerson SL, Denis L et al.. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011.
33. Patel PM, Suciu S, Mortier L et al.. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47: 1476-1483.
34. Decitabine (Dacogen) for myelodysplastic syndromes. Med Lett Drugs Ther 2006; 48: 91-92.
35. Plumb JA, Strathdee G, Sludden J et al.. Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-6044.
36. Appleton K, Mackay HJ, Judson I et al.. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25: 4603-4609.
37. Kantarjian H, Oki Y, Garcia-Manero G et al.. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
38. Liew DN, Kano H, Kondziolka D et al.. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011; 114: 769-779.
39. Ostermann S, Csajka C, Buclin T et al.. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10: 3728-3736.
40. Cashen AF, Shah AK, Todt L et al.. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008; 61: 759-766.
41. Hong M, Puaux AL, Huang C et al.. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71: 6997-7009.
42. Fratta E, Sigalotti L, Colizzi F et al.. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010; 223: 352-358.